EDITORIAL

Onset of psoriasis in patients receiving anti-TNF agents

A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents

C Ritchlin¹, F Tausk²

¹ Clinical Immunology Research Center, Allergy, Immunology and Rheumatology Division, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA
² Department of Dermatology, University of Rochester School of Medicine & Dentistry, Rochester, NY, USAC Ritchlin, Clinical Immunology Research Center, Allergy, Immunology and Rheumatology Division, University of Rochester School of Medicine & Dentistry, Rochester, New York, USA

Correspondence to:
Correspondence to:
C Ritchlin
christopher_ritchlin@urmc.rochester.edu

Accepted 14 August 2006

The first 150 words of the full text of this article appear below.

Life is a paradox. Every truth has its counterpart which contradicts it, and every philosopher supplies the logic for his own undoing.
Elbert Hubbard

In the past decade, tumour necrosis factor (TNF) antagonists have been found to be remarkably effective for the treatment of immune-mediated inflammatory disorders such as rheumatoid arthritis and Crohn’s disease.¹ These agents also dramatically lessen inflammation and improve the quality of life in patients with psoriasis and psoriatic arthritis.² The TNF-blocking agents have been relatively safe, although some concerns have been raised on the basis of a recent meta-analysis of trial data that identified an increased risk of serious infections and solid malignancy in a small percentage of patients treated with anti-TNF antibodies.³ Of late, attention has also focused on a wide spectrum of skin lesions arising in patients treated with TNF antagonists.⁴ The list is quite extensive, . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists

J D Carter
Ann Rheum Dis 2006 65: 1680. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Harrison, M J, Dixon, W G, Watson, K D, King, Y, Groves, R, Hyrich, K L, Symmons, D P M, and the British Society for Rheumatology Biologics, , on behalf of the BSRBR, (2009). Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor {alpha} therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 68: 209-215 [Abstract] [Full Text]  
• Paltiel, M., Gober, L. M., Deng, A., Mikdashi, J., Alexeeva, I., Saini, S. S., Gaspari, A. A. (2008). Immediate Type I Hypersensitivity Response Implicated in Worsening Injection Site Reactions to Adalimumab. Arch Dermatol 144: 1190-1194 [Abstract] [Full Text]  
• Carter, J D, Gerard, H C, Hudson, A P (2008). Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis 67: 1181-1183 [Abstract] [Full Text]  
• de Gannes, G. C., Ghoreishi, M., Pope, J., Russell, A., Bell, D., Adams, S., Shojania, K., Martinka, M., Dutz, J. P. (2007). Psoriasiform Eruptions During Anti TNF-{alpha} Treatment: Psoriasis or Not? Reply. Arch Dermatol 143: 1595-1595 [Full Text]  

eLetters:

Read all eLetters

Tumour necrosis factor alpha antagonist-induced psoriasis: A mystery

Jean-David Cohen, et al.

Ann Rheum Dis Online, 9 Jan 2007 [Full text]